Vir(VIR) - 2025 Q1 - Quarterly Results
Vir(US:VIR)2025-05-07 20:13– Initiated Phase 3 registrational ECLIPSE program in chronic hepatitis delta with first patient enrolled in Q1 2025; Program received U.S. FDA Breakthrough and Fast Track designations and EMA PRIME and Orphan Drug designations Exhibit 99.1 Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results – Dose escalation continues for PRO-XTEN™ dual-masked T-cell engagers VIR-5818 (HER2) and VIR-5500 (PSMA) – On track to initiate a Phase 1 study of VIR-5525, the PRO-XTEN™ dual-m ...